

## **Product datasheet for TL306875V**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ACOT7 Human shRNA Lentiviral Particle (Locus ID 11332)**

**Product data:** 

**Product Type:** shRNA Lentiviral Particles

**Product Name:** ACOT7 Human shRNA Lentiviral Particle (Locus ID 11332)

**Locus ID:** 11332

Synonyms: ACH1; ACT; BACH; CTE-II; hBACH; LACH; LACH1

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** BACH - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 007274, NM 181862, NM 181863, NM 181864, NM 181865, NM 181866, NM 007274.1,

NM 007274.2, NM 007274.3, NM 181864.1, NM 181864.2, NM 181865.1, NM 181865.2,

NM 181866.1, NM 181866.2, NM 181863.1, BC017365, BC017365.2, BM807217,

NM 181864.3, NM 181866.3, NM 007274.4, NM 181865.3

UniProt ID: 000154

**Summary:** This gene encodes a member of the acyl coenzyme family. The encoded protein hydrolyzes

the CoA thioester of palmitoyl-CoA and other long-chain fatty acids. Decreased expression of

this gene may be associated with mesial temporal lobe epilepsy. Alternatively spliced

transcript variants encoding distinct isoforms with different subcellular locations have been

characterized. [provided by RefSeq, Jul 2008]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).